Abstract
LY303366 is a new semisynthetic echinocandin derivative with potent, broad-spectrum fungicidal activity. We investigated the in vitro activity of LY303366, amphotericin B, flucytosine (5FC), fluconazole, and itraconazole against 435 clinical yeast isolates (413 Candida and 22 Saccharomyces cerevisiae isolates) obtained from over 30 different medical centers. MICs for all five antifungal agents were determined by the National Committee for Clinical Laboratory Standards method with RPMI 1640 test medium. LY303366 was also tested in antibiotic medium 3 as specified by the manufacturer. Overall, LY303366 was quite active against all of the yeast isolates when tested in RPMI 1640 (MIC at which 90% of the isolates are inhibited [MIC90], 1.0 microg/ml) but appeared to be considerably more potent when tested in antibiotic medium 3 (MIC90, 0.03 microg/ml). When tested in antibiotic medium 3, LY303366 was 16- to >2,000-fold more active than itraconazole, fluconazole, amphotericin B, or 5FC against all species except Candida parapsilosis. When tested in RPMI 1640, LY303366 was comparable to amphotericin B and itraconazole and more active than fluconazole and 5FC. All of the isolates for which fluconazole and itraconazole had elevated MICs (> or = 128 and > or = 2.0 microg/ml, respectively) were inhibited by < or = 0.007 microg of LY303366/ml when tested in antibiotic medium 3 and < or = 0.5 microg/ml when tested in RPMI 1640. Based on these studies, LY303366 has promising antifungal activity and warrants further in vitro and in vivo investigation.
Full Text
The Full Text of this article is available as a PDF (182.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Gordee R. S., Zeckner D. J., Ellis L. F., Thakkar A. L., Howard L. C. In vitro and in vivo anti-Candida activity and toxicology of LY121019. J Antibiot (Tokyo) 1984 Sep;37(9):1054–1065. doi: 10.7164/antibiotics.37.1054. [DOI] [PubMed] [Google Scholar]
- Pfaller M. A., Bale M., Buschelman B., Lancaster M., Espinel-Ingroff A., Rex J. H., Rinaldi M. G., Cooper C. R., McGinnis M. R. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol. 1995 May;33(5):1104–1107. doi: 10.1128/jcm.33.5.1104-1107.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pfaller M. A., Gerarden T., Yu M., Wenzel R. P. Influence of in vitro susceptibility testing conditions on the anti-candidal activity of LY121019. Diagn Microbiol Infect Dis. 1988 Sep;11(1):1–9. doi: 10.1016/0732-8893(88)90067-3. [DOI] [PubMed] [Google Scholar]
- Rex J. H., Pfaller M. A., Lancaster M., Odds F. C., Bolmström A., Rinaldi M. G. Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole. J Clin Microbiol. 1996 Apr;34(4):816–817. doi: 10.1128/jcm.34.4.816-817.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]